Ciltacabtagene autoleucel

Phase 2Cell therapy

Ciltacabtagene autoleucel is a cell therapy that works as a BCMA CAR-T.[2] It is being investigated across 3 indications, with its most advanced program in Phase 2.[1]

Ciltacabtagene autoleucel is one of 55 cell therapy programs targeting Recurrent Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Multiple MyelomaRecruiting

MyelomaActive, not recruiting

Multiple MyelomaRecruiting

Recurrent Multiple MyelomaPhase 2

Recruiting

MyelomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

45 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

15 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 8

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 9

Elranatamab

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Multiple Myeloma

NCT07093554

Q2 2028

Phase 1Recruiting

Multiple Myeloma

NCT06623630

Q3 2031

Phase 2Recruiting

Recurrent Multiple Myeloma

NCT06940297

Q4 2037

Recruiting

Myeloma Multiple

NCT06855121

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Recruiting·WWashington University School of Medicine·Phase 1·NCT06623630·16 enrolled

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·MMedical College of Wisconsin·Phase 1·NCT07093554·31 enrolled

Myeloma1 trial

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Active, not recruiting·—·Phase 2·NCT05767359·20 enrolled

Recurrent Multiple Myeloma1 trial

DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy

Recruiting·MMayo Clinic·Phase 2·NCT06940297·44 enrolled

Myeloma Multiple1 trial

The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

Recruiting·SSt. Olavs Hospital··NCT06855121·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ciltacabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciltacabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciltacabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 2 publications indexed for Ciltacabtagene autoleucel. U.S. National Library of Medicine.
[5]
SEC EDGAR — St. Olavs Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: BCMA CAR-T[2]
Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SSt. Olavs Hospital

Key Publications[4]

Two-Year Follow-Up of BCMA CAR-T in Multiple Myeloma

BloodAug 10, 2023DOI: 10.1182/blood.2023020145

Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: CARTITUDE-4

N Engl J MedJun 5, 2023DOI: 10.1056/NEJMoa2303379

Ciltacabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q3 2031

Q4 2037

Trials by Indication[1]

Multiple Myeloma2 trials

Myeloma1 trial

Recurrent Multiple Myeloma1 trial

Myeloma Multiple1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News